natgillin/translations-raw huggingface dataset:
During postmarketing experience, hypersensitivity reactions with very rare occurrence of fatal outcome, have been reported in association with trabectedin administration either alone or in combination with PLD (see sections 4.3 and 4.8).
V okviru izkušenj v obdobju trženja je prišlo do preobčutljivostnih reakcij z zelo redkim nastopom smrtnega izida, o katerih so poročali v povezavi z dajanjem trabektedina samega ali v kombinaciji s PLD (glejte poglavji 4.3 in 4.8).
During post–marketing surveillance, cases of interference between daptomycin and particular reagents used in some assays of prothrombin time/international normalised ratio (PT/INR) have been reported.
Med postmarketinškim nadzorovanjem so poročali o primerih interference med daptomicinom in določenimi reagenti, ki se uporabljajo v nekaterih testih za določanje protrombinskega časa/mednarodno umerjenega razmerja (PČ/INR).
During pregnancy
Med nosečnostjo
during pregnancy (see section 4.6) with severe uncontrolled hypertension and subacute bacterial endocarditis.
med nosečnostjo (glejte poglavje 4.6), pri bolnikih s hudo neobvladano hipertenzijo in subakutnim bakterijskim endokarditisom.
During pregnancy and breast-feeding, IDELVION should be given only if it is clearly needed.
Zdravilo IDELVION uporabljamo med nosečnostjo in dojenjem le, če je nujno potrebno.
During pregnancy and breast-feeding, Voncento should be given only if it is clearly needed.
Zdravilo Voncento uporabljamo med nosečnostjo in dojenjem le, če je nujno potrebno.
During pregnancy and lactation,
Nosečnost in dojenje.
During pregnancy and lactation.
Med nosečnostjo in dojenjem.
During pregnancy and lactation.
Nosečnost in dojenje.
During pregnancy, an effective antiepileptic rufinamide treatment must not be interrupted, since the aggravation of the illness is detrimental to both the mother and the foetus.
V nosečnosti učinkovitega antiepileptičnega zdravljenja z rufinamidom ne smemo prekiniti, ker je poslabšanje bolezni škodljivo tako za mater kot za plod.
During pregnancy.
Med nosečnostjo.
During Prolia treatment, patients should be advised to report new or unusual thigh, hip, or groin pain.
Bolnikom je treba naročiti, da morajo med zdravljenjem z zdravilom Prolia zdravniku poročati o novi ali nenavadni bolečini v stegnu, kolku ali dimljah.
During Rapamune therapy with or without CsA, patients should be monitored for elevated lipids, and patients administered an HMG-CoA reductase inhibitor and/or fibrate should be monitored for the possible development of rhabdomyolysis and other adverse reactions, as described in the respective Summary of Product Characteristics of these agents.
Med zdravljenjem z zdravilom Rapamune s ciklosporinom A ali brez njega je treba bolnike spremljati zaradi možnosti zvišanih lipidov in bolnike, ki prejemajo zaviralec reduktaze HMG-CoA in/ali fibrat, spremljati glede možnega razvoja rabdomiolize in drugih neželenih učinkov, ki so opisani v ustreznih povzetkih glavnih značilnosti teh zdravil.
During remission induction when rapid cell lysis is occurring, uric acid levels in blood and urine should be monitored as hyperuricaemia and/or hyperuricosuria may develop, with the risk of uric acid nephropathy.
Med indukcijo remisije, ko prihaja do hitre celične lize, je treba spremljati vrednost sečne kisline v krvi in urinu, saj se lahko razvije hiperurikemija in/ali hiperurikozurija s tveganjem nefropatije zaradi sečne kisline.
During repeated administration, the maximum reduction in blood pressure with any dose is generally attained within 2–4 weeks and is sustained during long-term therapy.
Med večkratno uporabo je največje znižanje krvnega tlaka pri vseh odmerkih praviloma doseženo v 2 do 4 tednih in se med dolgotrajnim zdravljenjem ohrani.
During routine laboratory assessments, in patients who had TSH < 5 μU/mL before treatment, elevations of TSH to ≥ 10 μU/mL occurred in 32.2% of patients receiving axitinib.
Med rutinskimi laboratorijskimi preiskavami je pri bolnikih s koncentracijo TSH < 5 μU/ml pred zdravljenjem do povečanj koncentracij TSH na ≥ 10 μU/ml prišlo pri 32,2 % bolnikov, ki so prejemali aksitinib.
During routine laboratory monitoring in the 12 week controlled phase, 3% of patients in the placebo group and 1% in the tocilizumab group had a decrease in platelet count to ≤ 100 x 103/µl.
Med rutinskim laboratorijskim spremljanjem v 12-tedenski kontrolirani fazi se je število trombocitov zmanjšalo na ≤ 100 x 103/µl pri 3 % bolnikov v skupini, ki je prejemala placebo in pri 1 % v skupini, ki je prejemala tocilizumab.
During routine laboratory monitoring in the 12 week controlled phase, elevation in ALT or AST ≥ 3 x ULN occurred in 5% and 3% of patients, respectively, in the tocilizumab group, and 0% in the placebo group.
Med rutinskim laboratorijskim spremljanjem v 12-tedenski, kontrolirani fazi se je pri bolnikih v skupini, ki je prejemala tocilizumab, dvig ALT na ≥ 3-kratno ZMN pojavil pri 5 % bolnikov (v skupini, ki je prejemala placebo pri 0 %), dvig AST na ≥ 3-kratno ZMN pa pri 3 % bolnikov (v skupini, ki je prejemala placebo pri 0 %).
During routine laboratory monitoring in the tocilizumab 6 month clinical trial SC-I, none of the patients on the SC weekly dose had a decrease in platelet count to ≤50 × 103 / μl.
V okviru rutinskega laboratorijskega spremljanja v šestmesečnem kontroliranem kliničnem preskušanju SC-I se ni število trombocitov zmanjšalo ≤ 50 x 103/µl pri nobenem od bolnikov, ki so prejemali subkutani tedenski odmerek.
During routine laboratory monitoring in the tocilizumab 6 month controlled clinical trial SC-I, 19% of patients experienced sustained elevations in total cholesterol > 6.2 mmol/l (240 mg/dl), with 9% experiencing a sustained increase in LDL to  4.1 mmol/l (160 mg/dl) on the subcutaneous weekly dose.
V okviru rutinskega laboratorijskega spremljanja v šestmesečnem kontroliranem kliničnem preskušanju SC-I se je pri 19 % bolnikov, ki so prejemali subkutani tedenski odmerek, pojavilo dolgotrajno zvišanje celotnega holesterola na > 6,2 mmol/l (240 mg/dl), pri 9 % bolnikov, ki so prejemali subkutani tedenski odmerek, pa dolgotrajno zvišanje LDL na ≥ 4,1 mmol/l (160 mg/dl).
During routine laboratory monitoring in the tocilizumab 6 month controlled clinical trial SC-I, a decrease in neutrophil count below 1 × 109/L occurred in 2.9% of patients on the subcutaneous weekly dose.
V šestmesečnem kontroliranem kliničnem preskušanju SC-I se je število nevtrofilcev zmanjšalo pod 1 x 109/l pri 2,9 % bolnikov, ki so prejemali subkutani tedenski odmerek.
During routine laboratory monitoring in the tocilizumab 6-month controlled clinical trial SC-I, elevation in ALT or AST ≥3 x ULN occurred in 6.5% and 1.4% of patients, respectively on the subcutaneous weekly dose.
V okviru rutinskega laboratorijskega spremljanja v šestmesečnem kliničnem preskušanju SC-I se je zvišanje ALT ≥ 3 x ZMN pojavilo pri 6,5 % bolnikov, ki so prejemali subkutani tedenski odmerek, zvišanje AST≥ 3 x ZMN pa pri 1,4 % bolnikov, ki so prejemali subkutani tedenski odmerek.
During routine laboratory monitoring in the tocilizumab all exposure population, elevation in total cholesterol >1.5-2 x ULN occurred in one patient (0.5%) and elevation in LDL >1.5-2 x ULN in one patient (0.5%).
Med rutinskim laboratorijskim spremljanjem se je dvig celokupnega holesterola > 1,5 x ZMN do 2 x ZMN pojavil pri enem bolniku (0,5 %) v celotni populaciji, ki je prejemala tocilizumab.
During routine signal detection activities, a review of five case reports of high level term amyloidosis cases related to enfuvirtide was extracted from Eudravigilance.
Med rutinskimi aktivnostmi za odkrivanje signalov je bilo iz podatkovne baze Eudravigilance v povezavi z enfuvirtidom pridobljenih pet poročil o amiloidozi, zavedeni po najmanj specifičnem izrazu klasifikacije neželenega učinka (HLT – high level term).
During solvent transfer, wet the powder completely by gently tilting the powder vial.
Med prenosom vehikla prašek povsem omočite tako, da vialo s praškom nežno nagnete.
During storage, a white deposit and clear supernatant can be observed.
Med shranjevanjem se lahko pojavita bela usedlina in bister supernatant.
During surgery on the knee, the suspension is placed into the defect in the patient’s cartilage.
Med operacijo kolena se suspenzija nanese na mesto okvare bolnikovega hrustanca.
During tadalafil 20 mg and 40 mg once daily dosing, steady-state plasma concentrations are attained within 5 days, and exposure is approximately 1.5 fold of that after a single dose.
Ravnotežno stanje je pri odmerkih 20 mg do 40 mg doseženo v petih dneh, biološka uporabnost pa je približno 1,5- krat večja kot po enkratnem odmerku.
During Tamiflu treatment, rare events have been reported that include
Med zdravljenjem z zdravilom Tamiflu so poročali o redkih dogodkih, ki vključujejo:
During Tasigna treatment, you may also have some abnormal blood test results such as low level of blood cells (white cells, red cells, platelets), high blood level of lipase or amylase (pancreas function), high blood level of bilirubin (liver function) or high blood level of creatinine (kidney function), low or high blood level of insulin (a hormone regulating blood sugar level), low or high level of sugar, or high level of fats in the blood.
V času zdravljenja z zdravilom Tasigna lahko pride tudi do nenormalnih izvidov nekaterih krvnih preiskav, kot so nizko število krvnih celic (belih ali rdečih krvnih celic ali trombocitov), do zvišanih ravni lipaze ali amilaze (kar kaže delovanje trebušne slinavke), zvišane ravni bilirubina v krvi (kar kaže delovanje jeter) ali zvišane ravni kreatinina v krvi (kar kaže delovanje ledvic), znižane ali zvišane ravni insulina v krvi (insulin je hormon, ki uravnava raven krvnega sladkorja), znižane ali zvišane ravni sladkorja v krvi ali previsoke ravni maščob v krvi.
During that 24-hour period, the first dose of plerixafor 0.24 mg/kg or placebo was administered 10-11 hours prior to apheresis.
Med navedenim 24-urnim obdobjem je bil prvi odmerek 0,24 mg/kg pleriksaforja ali placeba injiciran 10- 11 ur pred aferezo.
During that time the solution may be stored at 15°C-30°C or refrigerated.
V tem času se raztopina lahko shrani pri 15 °C-30 °C ali v hladilniku.
During the 1 month Induction phase of treatment, DepoCyte was administered intrathecally as 50 mg every 2 weeks, and unencapsulated cytarabine as 50 mg twice a week.
V enomesečni fazi začetnega zdravljenja so intratekalno prejemali 50 mg zdravila DepoCyte vsaka 2 tedna in 50 mg neinkapsuliranega citarabina dvakrat tedensko.
During the 10-week acute treatment period, suicidal behaviours were reported (duloxetine 0/333 [0%], fluoxetine 2/225 [0.9%], placebo 1/220 [0.5%]).
Med 10-tedenskim obdobjem akutnega zdravljenja so poročali o samomorilnem vedenju (duloksetin 0/333 [0 %], fluoksetin 2/225 [0,9 %], placebo 1/220 [0,5 %]).
During the 12 week run-in period, addition and titration of insulin glargine resulted approximately in an HbA1c decrease of 1%.
Med 12-tedenskim obdobjem uvajanja sta dodatek in titriranje insulina glargina povzročila znižanje HbA1c za približno 1 %.
During the 12-month treatment period, adverse reactions were reported in 44.5% (53/119), 41.4% (48/116), and 44.0% (51/116) and serious adverse reactions were reported in 2.5% (3/119), 2.6% (3/116) and 0.9% (1/116) of patients treated in the three treatment groups, respectively.
Med 12-mesečnim obdobjem zdravljenja so o neželenih učinkih poročali pri 44,5 % (53/119), 41,4 % (48/116) oziroma 44,0 % (51/116) bolnikov, ki so se zdravili v teh treh skupinah, o resnih neželenih učinkih pa pri 2,5 % (3/119), 2,6 % (3/116) oziroma 0,9 % (1/116) zdravljenjih bolnikov.
During the 12-week pre-filled pen period of the sub-study, there were no deaths or related SAEs.
Med 12-tedenskim obdobjem podštudije uporabe napolnjenega injekcijskega peresnika niso poročali o smrtnih primerih ali resnih neželenih učinkih.
During the 24 week, placebo controlled, Phase 3 studies, adverse reactions related to increased blood pressure (e.g., hypertension, blood pressure increased) were reported in 0.9% (7/738) of patients treated with lumacaftor/ivacaftor and in no patients who received placebo.
Med 24-tedenskimi študijami 3. faze, kontroliranimi s placebom, so pri 0,9 % (7/738) bolnikov, zdravljenih z lumakaftorjem/ivakaftorjem, in pri nobenem od bolnikov, ki so prejemali placebo, poročali o neželenih učinkih, povezanih z zvišanim krvnim tlakom (npr. hipertenziji, zvišanem krvnem tlaku).
During the 24-week double-blind phase, patients received either 5 mg/kg infliximab or placebo at weeks 0, 2, 6, 14, and 22 (100 patients in each group).
V tedenski dvojno slepi fazi študije so bolniki prejemali bodisi 5 mg/kg infliksimaba ali pa placebo v 0., 2., 6., 14. in 22. tednu (100 bolnikov v vsaki skupini).
During the 24-week, placebo-controlled, Phase 3 studies, the incidence of combined menstrual abnormality events (amenorrhoea, dysmenorrhoea, menorrhagia, menstruation irregular, metrorrhagia, oligomenorrhoea, and polymenorrhoea) was 9.9 % in lumacaftor/ivacaftor-treated female patients and 1.7% in placebo-treated females.
Med 24-tedenskimi, s placebom kontroliranimi študijami 3. faze je bila incidenca dogodkov združenih motenj menstrualnega ciklusa (amenoreja, dismenoreja, menoragija, neredna menstruacija, metroragija, oligomenoreja in polimenoreja) 9,9 % pri bolnicah, zdravljenih z lumakaftorjem/ivakaftorjem, in 1,7 % pri ženskah, ki so prejemale placebo.
During the 24-week, placebo-controlled, Phase 3 studies, the incidence of maximum transaminase (ALT or AST) levels >8, >5, and >3 x ULN were 0.8%, 2.0%, and 5.2%; and 0.5%, 1.9%, and 5.1% in lumacaftor/ivacaftor- and placebo-treated patients, respectively.
Med 24-tedenskimi študijami 3. faze, kontroliranimi s placebom, so bile incidence najvišjih ravni transaminaz (ALT ali AST) >8, >5 oziroma >3 x ULN 0,8 %, 2,0 % oziroma 5,2 %; in 0,5 %, 1,9 % oziroma 5,1 % pri bolnikih, ki so prejemali lumakaftor/ivakaftor oziroma placebo.
During the 24-week, placebo-controlled, Phase 3 studies, the incidence of respiratory adverse reactions (e.g., chest discomfort, dyspnoea, and respiration abnormal) was 26.3% in lumacaftor/ivacaftor-treated patients compared to 17.0% in patients who received placebo.
Med 24-tedenskimi, s placebom kontroliranimi študijami 3. faze je bila incidenca respiracijskih neželenih učinkov (npr. neugodje v prsih, dispneja in nenormalno dihanje) pri bolnikih, zdravljenih z lumakaftorjem/ivakaftorjem, 26,3 %, pri bolnikih, ki so prejemali placebo, pa 17,0 %.
During the 26 weeks, there were 12 serious events in 235 patients (5.1%) using liraglutide, whereas there were 6 serious adverse events in 232 patients (2.6%) using exenatide.
V 26 tednih se je pojavilo 12 resnih neželenih učinkov pri 235 bolnikih (5,1 %), ki so prejemali liraglutid, in 6 resnih neželenih učinkov pri 232 bolnikih (2,6 %), ki so prejemali eksenatid.
During the 2nd and 3rd trimester of pregnancy mean values of these parameters were comparable.
Med 2. in 3.trimesečjem nosečnosti so bile povprečne vrednosti teh parametrov primerljive.
During the 33-week open-label transition/maintenance period of the long-term recurrence prevention trial, 12% of Xeplion-treated subjects met this criterion (weight gain of ≥ 7% from double-blind phase to endpoint); the mean (SD) weight change from open-label baseline was + 0.7 (4.79) kg.
Med 33-tedenskim odprtim prehodnim/vzdrževalnim obdobjem preskušanja dolgotrajnega preprečevanja ponovitve bolezni je to merilo doseglo 12% preiskovancev, ki so jih zdravili z zdravilom Xeplion (zvečanje telesne mase za  7% od dvojno slepe faze do zaključka); povprečna sprememba telesne mase (standardni odklon) od začetka odprte faze je bila +0,7 (4,79) kg.
During the 52-week placebo- controlled double blind treatment phase 14.4% of the duloxetine-treated patients and 33.1% of the placebo-treated patients experience a return of their depressive symptoms (p < 0.001).
V fazi 52-tedenskega s placebom kontroliranega dvojno slepega zdravljenja je povratek simptomov depresije občutilo 14,4 % bolnikov, ki so se zdravili z duloksetinom, in 33,1 % bolnikov, ki so se zdravili s placebom (p < 0,001).
During the 52-week placebo- controlled double blind treatment phase 14.4% of the duloxetine-treated patients and 33.1% of the placebo-treated patients experience a return of their depressive symptoms (p<0.001).
V fazi 52-tedenskega s placebom kontroliranega dvojno slepega zdravljenja je povratek simptomov depresije občutilo 14,4 % bolnikov, ki so se zdravili z duloksetinom, in 33,1 % bolnikov, ki so se zdravili s placebom (p < 0,001).
During the 6-month controlled clinical trials, the overall rate of gastrointestinal perforation was 0.26 events per 100 patient years with tocilizumab therapy.
Med šestmesečnimi kontroliranimi kliničnimi preskušanji je bil celokupni delež perforacij v prebavilih med uporabo tocilizumaba 0,26 na 100 bolnik-let.
During the 6-month controlled period, in SC-I, the frequency of injection site reactions was 10.1% (64/631) and 2.4% (15/631) for the subcutaneous tocilizumab and the subcutaneous placebo ( intravenous group) weekly injections, respectively.
V 6-mesečnem kontroliranem obdobju je bila v SC-I pogostnost reakcij na mestu injiciranja 10,1 % (64/631) za subkutani tocilizumab in 2,4 % (15/631) za tedenske injekcije subkutanega placeba (intravenska skupina).
During the 6-month controlled trials transient elevations in ALT/AST > 3 x ULN were observed in 2.1% of patients on tocilizumab 8 mg/kg compared to 4.9% of patients on MTX and in 6.5% of patients who received 8 mg/kg tocilizumab plus DMARDs compared to 1.5% of patients on placebo plus DMARDs.
V šestmesečnih kontroliranih kliničnih preskušanjih so prehodno zvišanje ALT/AST na > 3-kratno ZMN zabeležili pri 2,1 % bolnikov, ki so dobivali 8 mg/kg tocilizumaba, pri 4,9 % bolnikov, ki so dobivali metotreksat, pri 6,5 % bolnikov, ki so dobivali 8 mg/kg tocilizumaba v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili, ter pri 1,5 % tistih, ki so dobivali placebo v kombinaciji z imunomodulirajočimi antirevmatičnimi zdravili.
During the 6-month controlled trials, increases of lipid parameters such as total cholesterol, triglycerides, LDL cholesterol, and/or HDL cholesterol have been reported commonly.
Med šestmesečnimi kontroliranimi preskušanji je bil pogosto opisan porast vrednosti lipidov, npr. celotnega holesterola, trigliceridov, holesterola LDL in/ali holesterola HDL.
During the 8 week double-blind period, patients took modafinil at their established dose or placebo equivalent.
Med 8- tedenskim dvojno slepim preskušanjem so bolniki jemali modafinil ali placebo v ekvivalentnem odmreku.
During the ACI procedure it is important to ensure that a good, direct contact of the implanted cells with the defect bed is obtained as such contact is of paramount importance for optimal tissue regeneration.
Med postopkom ACI je pomembno, da zagotovite dober, neposredni stik vsajenih celic s poškodovano površino, ker je tovrsten stik bistvenega pomena za optimalno regeneracijo tkiva.
During the active treatment period, the incidence of suicide-related events was similar between the varenicline-treated and the placebo-treated subjects (11 vs.
V obdobju, v katerem so prejemali zdravilo, je bila pogostnost s samomorom povezanih dogodkov podobna med preiskovanci, ki so prejemali vareniklin, ter preiskovanci, ki so prejemali placebo (11 v primerjavi z 9,3 %).
During the clinical development program (N=3,063), hepatitis was reported in 0.5% of patients receiving combination antiretroviral therapy with PREZISTA/ritonavir.
V kliničnem preskušanju zdravila (n=3.063) se je hepatitis pojavil pri 0,5% bolnikov, ki so prejemali kombinirano protiretrovitusno zdravljenje PREZISTA/ritonavir.
During the clinical development program (N=3,063), severe skin reactions, which may be accompanied with fever and/or elevations of transaminases, have been reported in 0.4% of patients.
V kliničnem preskušanju darunavirja/ritonavirja (n=3.063) se je pri 0,4% bolnikov pojavil hud kožni izpuščaj, ki ga je lahko spremljala zvišana telesna temperatura in/ali zvvišane koncentracije transaminaz.
During the clinical development program of raltegravir in treatment-experienced patients, rash, irrespective of causality, was more commonly observed with regimens containing PREZISTA + raltegravir compared to those containing PREZISTA without raltegravir or raltegravir without PREZISTA.
Med kliničnim razvojem raltegravirja pri bolnikih z izkušnjami s protiretrovirusnim zdravljenjem se je izpuščaj, ne glede na vzrok, pojavljal pogosteje pri shemi odmerjanja zdravila PREZISTA skupaj z raltegravirjem v primerjavi s shemo odmerjanja, ki je vsebovala samo zdravilo PREZISTA ali samo raltegravir.
During the clinical trials, children less than 6 years of age on a prophylaxis regimen used an average dose of 50 IU/kg of ReFacto and experienced an average of 6.1 bleeding episodes per year.
Med kliničnimi preskušanji so otroci, mlajši od 6 let, na profilaktičnem režimu uporabljali povprečni odmerek 50 i.e./kg zdravila ReFacto in imeli povprečno po 6,1 epizode krvavitve na leto.
During the clinical trials, pigs were only fed with medicated feeding stuff containing valnemulin in different concentrations (depending on the disease) for up to 4 weeks (depending on the disease).
Med kliničnimi preskušanji so prašiče do štiri tedne (odvisno od bolezni) hranili le z zdravilno krmo, ki je vsebovala valnemulin v različnih koncentracijah (odvisno od bolezni).
During the concomitant phase, your doctor will start Temodal at a dose of 75 mg/m2 (usual dose).
Med fazo sočasnega zdravljenja vam bo zdravnik začel dajati zdravilo Temodal v odmerku 75 mg/m2 (običajni odmerek).
During the concomitant phase, your doctor will start Temozolomide Hexal at a dose of 75 mg/m2 (usual dose).
Med fazo sočasnega zdravljenja vam bo zdravnik začel dajati zdravilo Temozolomid Hexal v odmerku 75 mg/m2 (običajni odmerek).
During the CONFIRMS study, the percentages of patients who required treatment for gout flares (Day 1 through Month 6) were 31% and 25% for the febuxostat 80 mg and allopurinol groups, respectively.
Med študijo CONFIRMS je bil delež bolnikov, ki so potrebovali zdravljenje zaradi protina (od 1. dne do 6. meseca) 31 % oziroma 25 % pri skupini z 80 mg febuksostata oziroma alopurinolom.
During the controlled periods of the psoriasis and psoriatic arthritis clinical studies of ustekinumab, rash and urticaria have each been observed in < 1% of patients (see section 4.4).
Med nadzorovanim obdobjem kliničnih študij psoriaze in psoriatičnega artritisa z ustekinumabom so izpuščaje in urtikarijo opažali pri < 1% bolnikov.
During the controlled study of nmDMD, mean total cholesterol and triglycerides were normal at baseline and increased, reaching borderline high or high values.
Med kontrolirano študijo pri bolnikih z DMD zaradi nesmiselne mutacije so bile povprečne ravni skupnega holesterola in trigliceridov ob izhodišču normalne, nato pa so se zvišale do mejno visokih ali visokih vrednosti.
During the course of interferon (standard and pegylated)/ribavirin therapy lasting up to 48 weeks in patients ages 3 through 17 years, weight loss and growth inhibition were common.
Med kombinirano terapijo z interferonom (standardnim in pegiliranim)/ribavirinom, ki traja do 48 tednov, sta bila pri bolnikih, starih od 3 do 17 let, hujšanje in zastoj rasti pogosta.
During the course of therapy lasting up to 48 weeks in patients ages 3 through 17 years, weight loss and growth inhibition were common.
Med terapijo, ki je trajala do 48 tednov, sta bila pri bolnikih, starih od 3 do 17 let, pogosta hujšanje in zastoj rasti.
During the course of treatment, appropriate determination of factor IX levels is advised to guide the dose to be administered and the frequency of repeated injections.
Med zdravljenjem svetujemo ustrezno spremljanje ravni faktorja IX za določanje višine danega odmerka in pogostnosti ponavljanih injiciranj.